SCHEMBL15540970

SCHEMBL15540970

COc1cc2[nH]nc(C#N)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.49
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
USP8 P40818 1/20 0.40
USP7 Q93009 1/20 0.40
PDE3A Q14432 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAPK1 P28482 2/20 0.38
NTRK3 Q16288 1/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
MAPK10 P53779 2/20 0.36
RIPK1 Q13546 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17221540 0.77 NTRK1 (0.50) NTRK1KDM4EALDH1A1HPGDUSP8
SCHEMBL4013912 0.77 NTRK1 (0.44) NTRK1KDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL11708958 0.74 KDM4E (0.46) KDM4ESMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL30459758 0.74 ADORA2A (0.50) KDM4ESMN1; SMN2ALDH1A1HPGDPDE3A
SCHEMBL17683153 0.74 ADORA2A (0.50) KDM4ESMN1; SMN2ALDH1A1HPGDPDE3A
SCHEMBL29936759 0.73 NTRK1 (0.38) NTRK1MAPK1NTRK3LRRK2
SCHEMBL15542269 0.73 NTRK1 (0.40) NTRK1MAPK1NTRK3LRRK2
Hydrochloric Acid SCHEMBL11708649 0.73 KDM4E (0.45) KDM4ESMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL24358769 0.71 NTRK1 (0.38) NTRK1KDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL2865217 0.71 MAPK10 (0.46) KDM4EALDH1A1MAPK10RIPK1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867226-B1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2018-11-14 EP disclosed
CN-105121429-B Complement pathway modulators and uses thereof 诺华股份有限公司 2017-12-12 CN disclosed
US-9815819-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2017-11-14 US disclosed
US-9815819-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2017-11-14 US disclosed
CN-105121429-A Complement pathway modulators and uses thereof NOVARTIS AG 2015-12-02 CN disclosed
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 US disclosed
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 US disclosed
EP-2867226-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF Novartis AG (CH) 2015-05-06 EP disclosed
WO-2014002051-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2014-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF C5, C3AR1, C9 NTRK1 3612/4885KDM4E 3988/4885SMN1; SMN2 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.